BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3-13. [PMID: 22418883 DOI: 10.1055/s-0032-1306421] [Cited by in Crossref: 225] [Cited by in F6Publishing: 211] [Article Influence: 22.5] [Reference Citation Analysis]
Number Citing Articles
1 Kanno R, Koshizuka T, Miyazaki N, Kobayashi T, Ishioka K, Ozaki C, Chiba H, Suzutani T. Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture. Foods 2021;10:291. [PMID: 33535476 DOI: 10.3390/foods10020291] [Reference Citation Analysis]
2 Corbit KC, Wilson CG, Lowe D, Tran JL, Vera NB, Clasquin M, Mattis AN, Weiss EJ. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. JCI Insight 2019;5:131310. [PMID: 31393852 DOI: 10.1172/jci.insight.131310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Harrison SA. Nonalcoholic fatty liver disease and fibrosis progression: the good, the bad, and the unknown. Clin Gastroenterol Hepatol 2015;13:655-7. [PMID: 25478921 DOI: 10.1016/j.cgh.2014.11.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
4 Shi T, Wu L, Ma W, Ju L, Bai M, Chen X, Liu S, Yang X, Shi J. Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evid Based Complement Alternat Med 2020;2020:8749564. [PMID: 31998400 DOI: 10.1155/2020/8749564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
5 Snider NT, Griggs NW, Singla A, Moons DS, Weerasinghe SV, Lok AS, Ruan C, Burant CF, Conjeevaram HS, Omary MB. CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology 2013;58:1790-800. [PMID: 23729294 DOI: 10.1002/hep.26525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, Xu J, Workman HC, Usborne AL, Hua H. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Front Pharmacol. 2018;9:410. [PMID: 29765319 DOI: 10.3389/fphar.2018.00410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
7 Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, Wamhoff BR, Mirshahi F, Contos MJ, Idowu M, Sanyal AJ. Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:12541. [PMID: 31467298 DOI: 10.1038/s41598-019-48746-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
8 Chen YC, Jeng WJ, Hsu CW, Lin CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol 2020;20:146. [PMID: 32397963 DOI: 10.1186/s12876-020-01289-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup.Clin Liver Dis (Hoboken). 2012;1:99-103. [PMID: 31186860 DOI: 10.1002/cld.81] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
10 Xu M, Zheng XM, Jiang F, Qiu WQ. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. J Cell Biochem 2018;119:5864-74. [PMID: 29575055 DOI: 10.1002/jcb.26776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tian J, Zhong R, Liu C, Tang Y, Gong J, Chang J, Lou J, Ke J, Li J, Zhang Y, Yang Y, Zhu Y, Gong Y, Xu Y, Liu P, Yu X, Xiao L, Du M, Yang L, Yuan J, Wang Y, Chen W, Wei S, Liang Y, Zhang X, He M, Wu T, Yao P, Miao X. Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study. Sci Rep 2016;6:31006. [PMID: 27484402 DOI: 10.1038/srep31006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
12 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Intern Med 2020;59:1931-7. [PMID: 32448832 DOI: 10.2169/internalmedicine.4398-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E; NASH CRN. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology 2016;151:1141-1154.e9. [PMID: 27569726 DOI: 10.1053/j.gastro.2016.08.027] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
14 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 168] [Article Influence: 49.5] [Reference Citation Analysis]
15 Ferreira DM, Simão AL, Rodrigues CM, Castro RE. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J 2014;281:2503-24. [PMID: 24702768 DOI: 10.1111/febs.12806] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
16 Schröder B, Roden M. Was bedeuten die neuen Diabetessubgruppen für Menschen mit Fettlebererkrankung? Diabetologe 2021;17:20-5. [DOI: 10.1007/s11428-020-00698-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer? European Journal of Internal Medicine 2017;46:1-5. [DOI: 10.1016/j.ejim.2017.06.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
18 Lee EH, Kim JY, Yang HR. Relationship Between Histological Features of Non-alcoholic Fatty Liver Disease and Ectopic Fat on Magnetic Resonance Imaging in Children and Adolescents. Front Pediatr 2021;9:685795. [PMID: 34178902 DOI: 10.3389/fped.2021.685795] [Reference Citation Analysis]
19 Bedossa P. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver Int. 2018;38 Suppl 1:64-66. [PMID: 29427497 DOI: 10.1111/liv.13653] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
20 Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49:531-539. [PMID: 30577089 DOI: 10.1111/hepr.13304] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
21 Barbois S, Arvieux C, Leroy V, Reche F, Stürm N, Borel A. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surgery for Obesity and Related Diseases 2017;13:1780-6. [DOI: 10.1016/j.soard.2017.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
22 Marcolino Assis-júnior E, Melo AT, Pereira VBM, Wong DVT, Sousa NRP, Oliveira CMG, Malveira LRC, Moreira LS, Souza MHLP, Almeida PRC, Lima-júnior RCP. Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan. Toxicology and Applied Pharmacology 2017;327:71-9. [DOI: 10.1016/j.taap.2017.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
23 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 21.5] [Reference Citation Analysis]
24 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 288] [Article Influence: 43.1] [Reference Citation Analysis]
25 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
26 Demirel-Yalciner T, Sozen E, Ozaltin E, Sahin A, Ozer NK. alpha-Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis. Biofactors 2021;47:403-13. [PMID: 34101924 DOI: 10.1002/biof.1700] [Reference Citation Analysis]
27 Bashiri A, Nesan D, Tavallaee G, Sue-chue-lam I, Chien K, Maguire GF, Naples M, Zhang J, Magomedova L, Adeli K, Cummins CL, Ng DS. Cellular cholesterol accumulation modulates high fat high sucrose (HFHS) diet-induced ER stress and hepatic inflammasome activation in the development of non-alcoholic steatohepatitis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2016;1861:594-605. [DOI: 10.1016/j.bbalip.2016.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
28 Pastore M, Grimaudo S, Pipitone RM, Lori G, Raggi C, Petta S, Marra F. Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Front Pharmacol 2019;10:604. [PMID: 31191323 DOI: 10.3389/fphar.2019.00604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kim H, Lee K, Lee KW, Yi NJ, Lee HW, Hong G, Choi Y, You T, Suh SW, Jang JJ. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28:521-529. [PMID: 24579874 DOI: 10.1111/ctr.12343] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
30 Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550-556. [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027] [Cited by in Crossref: 277] [Cited by in F6Publishing: 258] [Article Influence: 30.8] [Reference Citation Analysis]
31 Murtha-Lemekhova A, Fuchs J, Feiler S, Schulz E, Teroerde M, Kalkum E, Klotz R, Billeter A, Probst P, Hoffmann K. Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations. BMC Med 2022;20:47. [PMID: 35101037 DOI: 10.1186/s12916-022-02239-x] [Reference Citation Analysis]
32 Koutoukidis DA, Jebb SA, Tomlinson JW, Cobbold JF, Aveyard P. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
34 Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, Hamdorf J, Adams LA. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Am J Gastroenterol 2018;113:1484-93. [PMID: 29899440 DOI: 10.1038/s41395-018-0133-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
35 Kern B, Feurstein B, Fritz J, Fabritius C, Sucher R, Graziadei I, Bale R, Tilg H, Zoller H, Newsome P, Eschertzhuber S, Margreiter R, Öfner D, Schneeberger S. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur J Gastroenterol Hepatol 2019;31:205-10. [PMID: 30320609 DOI: 10.1097/MEG.0000000000001270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Tang S, Zhang J, Mei TT, Guo HQ, Wei XH, Zhang WY, Liu YL, Liang S, Fan ZP, Ma LX, Lin W, Liu YR, Qiu LX, Yu HB. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis. BMC Med Genet 2020;21:163. [PMID: 32811452 DOI: 10.1186/s12881-020-01098-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Zhang X, Ouyang J, Thung SN. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis. 2013;17:547-564, vii-viii. [PMID: 24099017 DOI: 10.1016/j.cld.2013.07.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
38 Zamboni M, Rossi AP, Fantin F, Budui SL, Zoico E, Zamboni GA, Mazzali G. Predictors of Ectopic Fat in Humans. Curr Obes Rep 2014;3:404-13. [PMID: 26626917 DOI: 10.1007/s13679-014-0126-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
39 Giraudi PJ, Giuricin M, Bonazza D, de Manzini N, Tiribelli C, Palmisano S, Rosso N. Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery. Int J Obes (Lond) 2021;45:374-82. [PMID: 32943763 DOI: 10.1038/s41366-020-00687-0] [Reference Citation Analysis]
40 Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:1028-33.e2. [PMID: 22610002 DOI: 10.1016/j.cgh.2012.05.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
41 Bril F, Barb D, Portillo-sanchez P, Biernacki D, Lomonaco R, Suman A, Weber MH, Budd JT, Lupi ME, Cusi K. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 2017;65:1132-44. [DOI: 10.1002/hep.28985] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 21.0] [Reference Citation Analysis]
42 Pirhonen J, Arola J, Sädevirta S, Luukkonen P, Karppinen SM, Pihlajaniemi T, Isomäki A, Hukkanen M, Yki-Järvinen H, Ikonen E. Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. PLoS One 2016;11:e0147804. [PMID: 26808140 DOI: 10.1371/journal.pone.0147804] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
43 Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66:84-95. [PMID: 28195363 DOI: 10.1002/hep.29113] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
44 Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) 2014;2014:526979. [PMID: 25763333 DOI: 10.1155/2014/526979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
45 Zhong L, Peng X, Wu C, Li Q, Chen Y, Wang M, Li Y, He K, Shi Y, Bie C, Tang S. Polysaccharides and flavonoids from cyclocarya paliurus modulate gut microbiota and attenuate hepatic steatosis, hyperglycemia, and hyperlipidemia in nonalcoholic fatty liver disease rats with type 2 diabetes mellitus. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-022-01080-5] [Reference Citation Analysis]
46 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Bozaykut P, Sahin A, Karademir B, Ozer NK. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis. Mechanisms of Ageing and Development 2016;157:17-29. [DOI: 10.1016/j.mad.2016.07.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
48 Torres-villalobos G, Hamdan-pérez N, Tovar AR, Ordaz-nava G, Martínez-benítez B, Torre-villalvazo I, Morán-ramos S, Díaz-villaseñor A, Noriega LG, Hiriart M, Medina-santillán R, Castillo-hernandez MDC, Méndez-sánchez N, Uribe M, Torres N. Combined high-fat diet and sustained high sucrose consumption promotes NAFLD in a murine model. Annals of Hepatology 2015;14:540-6. [DOI: 10.1016/s1665-2681(19)31176-7] [Cited by in Crossref: 15] [Article Influence: 2.1] [Reference Citation Analysis]
49 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
50 Al-Eryani L, Wahlang B, Falkner KC, Guardiola JJ, Clair HB, Prough RA, Cave M. Identification of Environmental Chemicals Associated with the Development of Toxicant-associated Fatty Liver Disease in Rodents. Toxicol Pathol 2015;43:482-97. [PMID: 25326588 DOI: 10.1177/0192623314549960] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
51 Ceccarelli V, Barchetta I, Cimini FA, Bertoccini L, Chiappetta C, Capoccia D, Carletti R, Di Cristofano C, Silecchia G, Fontana M, Leonetti F, Lenzi A, Baroni MG, Barone E, Cavallo MG. Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. Int J Mol Sci 2020;21:E9091. [PMID: 33260451 DOI: 10.3390/ijms21239091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
52 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
53 Inzaugarat ME, De Matteo E, Baz P, Lucero D, García CC, Gonzalez Ballerga E, Daruich J, Sorda JA, Wald MR, Cherñavsky AC. New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans. PLoS One 2017;12:e0172900. [PMID: 28257515 DOI: 10.1371/journal.pone.0172900] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
54 Wang C, Pai AK, Putra J. Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. J Clin Pathol 2022:jclinpath-2022-208246. [PMID: 35414523 DOI: 10.1136/jclinpath-2022-208246] [Reference Citation Analysis]
55 Dennis A, Kelly MD, Fernandes C, Mouchti S, Fallowfield JA, Hirschfield G, Pavlides M, Harrison S, Chakravarthy MV, Banerjee R, Sanyal A. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:575843. [PMID: 33584535 DOI: 10.3389/fendo.2020.575843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
56 Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1811-1822.e4. [PMID: 27003601 DOI: 10.1053/j.gastro.2016.03.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
57 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
58 Tanaka K, Masaki Y, Tanaka M, Miyazaki M, Enjoji M, Nakamuta M, Kato M, Nomura M, Inoguchi T, Kotoh K, Takayanagi R. Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J Gastroenterol 2014; 20(10): 2653-2663 [PMID: 24627601 DOI: 10.3748/wjg.v20.i10.2653] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
59 Westerkamp AC, Pully VV, Karimian G, Bomfati F, Veldhuis ZJ, Wiersema-Buist J, Hendriks BH, Lisman T, Porte RJ. Diffuse reflectance spectroscopy accurately quantifies various degrees of liver steatosis in murine models of fatty liver disease. J Transl Med 2015;13:309. [PMID: 26388419 DOI: 10.1186/s12967-015-0671-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
60 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
61 Schwen LO, Homeyer A, Schwier M, Dahmen U, Dirsch O, Schenk A, Kuepfer L, Preusser T, Schenk A. Zonated quantification of steatosis in an entire mouse liver. Comput Biol Med 2016;73:108-18. [PMID: 27104496 DOI: 10.1016/j.compbiomed.2016.04.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
62 Rajlawot K, Jiang T, Zhou J, Lin C, Kuang S, Chen J, Zhang Y, Yang H, Deng Y, He B, Hernando D, Reeder SB, Wang J. Accuracies of Chemical Shift In/Opposed Phase and Chemical Shift Encoded Magnetic Resonance Imaging to Detect Intratumoral Fat in Hepatocellular Carcinoma. J Magn Reson Imaging 2021;53:1791-802. [PMID: 33580551 DOI: 10.1002/jmri.27539] [Reference Citation Analysis]
63 Lakshman R, Shah R, Reyes-gordillo K, Varatharajalu R. Synergy between NAFLD and AFLD and potential biomarkers. Clinics and Research in Hepatology and Gastroenterology 2015;39:S29-34. [DOI: 10.1016/j.clinre.2015.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
64 Cataldo I, Sarcognato S, Sacchi D, Cacciatore M, Baciorri F, Mangia A, Cazzagon N, Guido M. Pathology of non-alcoholic fatty liver disease. Pathologica 2021;113:194-202. [PMID: 34294937 DOI: 10.32074/1591-951X-242] [Reference Citation Analysis]
65 Augustin S, Graupera I, Caballeria J; en nombre del grupo de trabajo sobre «Hígado graso no alcohólico» de la Societat Catalana de Digestologia. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc) 2017;149:542-8. [PMID: 28751080 DOI: 10.1016/j.medcli.2017.06.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
66 Cristofano M D, A F, Giacomo M D, C F, F B, D L, Rotondi Aufiero V, F M, E C, G M, V Z, M R, P B. Mechanisms underlying the hormetic effect of conjugated linoleic acid: Focus on Nrf2, mitochondria and NADPH oxidases. Free Radic Biol Med 2021;167:276-86. [PMID: 33753237 DOI: 10.1016/j.freeradbiomed.2021.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Iritani S, Akuta N, Kawamura Y, Kajiwara A, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saito S, Suzuki F, Arase Y, Ikeda K, Suzuki Y, Kumada H. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol 2020;20:368. [PMID: 33148171 DOI: 10.1186/s12876-020-01509-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Braun HA, Faasse SA, Vos MB. Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment. Gastroenterol Clin North Am 2018;47:949-68. [PMID: 30337043 DOI: 10.1016/j.gtc.2018.07.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
69 Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. Clin Transl Gastroenterol 2021;12:e00400. [PMID: 34506332 DOI: 10.14309/ctg.0000000000000400] [Reference Citation Analysis]
70 Ogawa K, Kobayashi T, Furukawa JI, Hanamatsu H, Nakamura A, Suzuki K, Kawagishi N, Ohara M, Umemura M, Nakai M, Sho T, Suda G, Morikawa K, Baba M, Furuya K, Terashita K, Kobayashi T, Onodera M, Horimoto T, Shinada K, Tsunematsu S, Tsunematsu I, Meguro T, Mitsuhashi T, Hato M, Higashino K, Shinohara Y, Sakamoto N. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. Sci Rep 2020;10:321. [PMID: 31941930 DOI: 10.1038/s41598-019-56947-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
71 Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-9.e4. [PMID: 23860502 DOI: 10.1053/j.gastro.2013.06.057] [Cited by in Crossref: 286] [Cited by in F6Publishing: 258] [Article Influence: 31.8] [Reference Citation Analysis]
72 Valva P, Rios D, Casciato P, Gadano A, Galdame O, Mullen E, Bertot G, de Matteo E, Preciado MV. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina. European Journal of Gastroenterology & Hepatology 2018;30:637-44. [DOI: 10.1097/meg.0000000000001079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
73 Vespasiani-Gentilucci U, Carotti S, Perrone G, Mazzarelli C, Galati G, Onetti-Muda A, Picardi A, Morini S. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int. 2015;35:569-581. [PMID: 24649857 DOI: 10.1111/liv.12531] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
74 Vos MB, Jin R, Konomi JV, Cleeton R, Cruz J, Karpen S, Rodriguez DS, Frediani JK, McCracken C, Welsh J. A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease. Pilot Feasibility Stud 2018;4:109. [PMID: 29992039 DOI: 10.1186/s40814-018-0306-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
75 Khalili M, King WC, Kleiner DE, Jain MK, Chung RT, Sulkowski M, Lisker-melman M, Wong DK, Ghany M, Sanyal A, Sterling RK. Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clinical Infectious Diseases 2020. [DOI: 10.1093/cid/ciaa1303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
76 Debes JD, Bohjanen PR, Boonstra A. Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection. J Clin Transl Hepatol. 2016;4:328-335. [PMID: 28097102 DOI: 10.14218/jcth.2016.00034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
77 Jung ES, Lee K, Yu E, Kang YK, Cho MY, Kim JM, Moon WS, Jeong JS, Park CK, Park JB, Kang DY, Sohn JH, Jin SY. Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease. J Pathol Transl Med 2016;50:190-6. [PMID: 27086596 DOI: 10.4132/jptm.2016.03.01] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
78 Terzo S, Mulè F, Caldara GF, Baldassano S, Puleio R, Vitale M, Cassata G, Ferrantelli V, Amato A. Pistachio Consumption Alleviates Inflammation and Improves Gut Microbiota Composition in Mice Fed a High-Fat Diet. Int J Mol Sci 2020;21:E365. [PMID: 31935892 DOI: 10.3390/ijms21010365] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
79 Prysyazhnyuk VP, Ushenko YA, Dubolazov AV, Ushenko AG, Ushenko VA. Polarization-dependent laser autofluorescence of the polycrystalline networks of blood plasma films in the task of liver pathology differentiation. Appl Opt 2016;55:B126-32. [PMID: 27140117 DOI: 10.1364/AO.55.00B126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
80 Cairoli V, De Matteo E, Rios D, Lezama C, Galoppo M, Casciato P, Mullen E, Giadans C, Bertot G, Preciado MV, Valva P. Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease. Sci Rep 2021;11:5129. [PMID: 33664397 DOI: 10.1038/s41598-021-84674-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
82 Sterling RK, King WC, Khalili M, Kleiner DE, Hinerman AS, Sulkowski M, Chung RT, Jain MK, Lisker-Melman MA, Wong DK, Ghany MG; HBV-HIV Cohort Study of the Hepatitis B Research Network. Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults. Dig Dis Sci 2021. [PMID: 33559089 DOI: 10.1007/s10620-021-06860-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 2016;16:141. [PMID: 27955628 DOI: 10.1186/s12876-016-0557-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
84 Nalbantoglu I, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9026-9037 [PMID: 25083076 DOI: 10.3748/wjg.v20.i27.9026] [Cited by in F6Publishing: 51] [Reference Citation Analysis]
85 Lefere S, Van de Velde F, Devisscher L, Bekaert M, Raevens S, Verhelst X, Van Nieuwenhove Y, Praet M, Hoorens A, Van Steenkiste C, Van Vlierberghe H, Lapauw B, Geerts A. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int J Obes (Lond) 2017;41:1207-13. [PMID: 28461687 DOI: 10.1038/ijo.2017.102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
86 Unamuno X, Gómez-Ambrosi J, Ramírez B, Rodríguez A, Becerril S, Valentí V, Moncada R, Silva C, Salvador J, Frühbeck G, Catalán V. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol Immunol 2021;18:1045-57. [PMID: 31551515 DOI: 10.1038/s41423-019-0296-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
87 Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014;31:30-43. [PMID: 24385405 DOI: 10.1007/s12325-013-0084-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
88 Josan S, Billingsley K, Orduna J, Park JM, Luong R, Yu L, Hurd R, Pfefferbaum A, Spielman D, Mayer D. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. NMR Biomed. 2015;28:1671-1677. [PMID: 26474216 DOI: 10.1002/nbm.3431] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
89 Pastore A, Alisi A, di Giovamberardino G, Crudele A, Ceccarelli S, Panera N, Dionisi-Vici C, Nobili V. Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. Int J Mol Sci 2014;15:21202-14. [PMID: 25407526 DOI: 10.3390/ijms151121202] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
90 Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ; American Association for the Study of Liver Diseases NASH Task Force. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021;73:2028-38. [PMID: 33111374 DOI: 10.1002/hep.31599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
91 Serenari M, Collaud C, Alvarez FA, de Santibañes M, Giunta D, Pekolj J, Ardiles V, de Santibañes E. Interstage Assessment of Remnant Liver Function in ALPPS Using Hepatobiliary Scintigraphy: Prediction of Posthepatectomy Liver Failure and Introduction of the HIBA Index. Ann Surg 2018;267:1141-7. [PMID: 28121683 DOI: 10.1097/SLA.0000000000002150] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 10.7] [Reference Citation Analysis]
92 Parra-Vargas M, Rodriguez-Echevarria R, Jimenez-Chillaron JC. Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review. Nutrients 2020;12:E3860. [PMID: 33348700 DOI: 10.3390/nu12123860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46-52. [PMID: 29404432 DOI: 10.1002/hep4.1019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
94 Fierbinteanu-Braticevici C, Sinescu C, Moldoveanu A, Petrisor A, Diaconu S, Cretoiu D, Braticevici B. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biol Toxicol 2017;33:5-14. [PMID: 27680752 DOI: 10.1007/s10565-016-9361-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
95 Tovoli F, Ferri S, Piscaglia F. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3909-14. [PMID: 32348210 DOI: 10.2174/1381612826666200429093648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
96 Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, Hino K, Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M. Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatol Commun 2018;2:58-68. [PMID: 29404513 DOI: 10.1002/hep4.1121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
97 Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015;35:562-568. [PMID: 24351080 DOI: 10.1111/liv.12442] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
98 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
99 Lefere S, Dupont E, De Guchtenaere A, Van Biervliet S, Velde SV, Verhelst X, Devisscher L, Van Vlierberghe H, Geerts A, De Bruyne R. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01277-5. [PMID: 34871812 DOI: 10.1016/j.cgh.2021.11.039] [Reference Citation Analysis]
100 Phieler J, Garcia-Martin R, Lambris JD, Chavakis T. The role of the complement system in metabolic organs and metabolic diseases. Semin Immunol. 2013;25:47-53. [PMID: 23684628 DOI: 10.1016/j.smim.2013.04.003] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
101 Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol 2015;14:789-806. [PMID: 26436351 DOI: 10.5604/16652681.1171749] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
102 Lee JI, Lee HW, Lee KS. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. World J Gastroenterol 2019; 25(33): 4959-4969 [PMID: 31543686 DOI: 10.3748/wjg.v25.i33.4959] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
103 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
104 Yeh MM, Brunt EM. Pathological Features of Fatty Liver Disease. Gastroenterology 2014;147:754-64. [DOI: 10.1053/j.gastro.2014.07.056] [Cited by in Crossref: 184] [Cited by in F6Publishing: 162] [Article Influence: 23.0] [Reference Citation Analysis]
105 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
106 Ze EY, Kim BJ, Jun DH, Kim JG, Kang H, Lee DY. The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. Dis Colon Rectum 2018;61:36-42. [PMID: 29219920 DOI: 10.1097/DCR.0000000000000973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
107 Xu Y, Lu LL, Liu SS, Du SX, Zhu HL, Dong QJ, Xin YN. Apolipoprotein A5 gene polymorphisms are associated with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2018;17:214-9. [PMID: 29735301 DOI: 10.1016/j.hbpd.2018.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
108 Satapathy SK, Tran QT, Kovalic AJ, Bontha SV, Jiang Y, Kedia S, Karri S, Mupparaju V, Podila PSB, Verma R, Maluf D, Mas V, Nair S, Eason JD, Bridges D, Kleiner DE. Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation. Clin Transl Gastroenterol 2021;12:e00302. [PMID: 33555168 DOI: 10.14309/ctg.0000000000000302] [Reference Citation Analysis]
109 Kleiner DE. Drugs and Toxins. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 673-779. [DOI: 10.1016/b978-0-7020-6697-9.00012-1] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
110 Roth K, Imran Z, Liu W, Petriello MC. Diet as an Exposure Source and Mediator of Per- and Polyfluoroalkyl Substance (PFAS) Toxicity. Front Toxicol 2020;2:601149. [DOI: 10.3389/ftox.2020.601149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Marmur J, Beshara S, Eggertsen G, Onelöv L, Albiin N, Danielsson O, Hultcrantz R, Stål P. Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease. BMC Gastroenterol 2018;18:78. [PMID: 29871592 DOI: 10.1186/s12876-018-0804-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
112 Imajo K, Tetlow L, Dennis A, Shumbayawonda E, Mouchti S, Kendall TJ, Fryer E, Yamanaka S, Honda Y, Kessoku T, Ogawa Y, Yoneda M, Saito S, Kelly C, Kelly MD, Banerjee R, Nakajima A. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. World J Gastroenterol 2021; 27(7): 609-623 [PMID: 33642832 DOI: 10.3748/wjg.v27.i7.609] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
113 Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN)., Harvard Consortium. Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care 2018;41:1251-9. [PMID: 29599296 DOI: 10.2337/dc18-0040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
114 Unalp-arida A, Ruhl CE. Liver fat scores predict liver disease mortality in the United States population. Aliment Pharmacol Ther 2018;48:1003-16. [DOI: 10.1111/apt.14967] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
115 Nelson SM, Hoskins JD, Lisanti C, Chaudhuri J. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population. J Ultrasound Med 2020;39:749-59. [PMID: 31647137 DOI: 10.1002/jum.15154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
116 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 18.1] [Reference Citation Analysis]
117 Sanyal AJ. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? BMC Med 2018;16:148. [PMID: 30139362 DOI: 10.1186/s12916-018-1149-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
118 Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2:1344-1355. [PMID: 30411081 DOI: 10.1002/hep4.1237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
119 Wahlang B, Beier JI, Clair HB, Bellis-Jones HJ, Falkner KC, McClain CJ, Cave MC. Toxicant-associated steatohepatitis. Toxicol Pathol 2013;41:343-60. [PMID: 23262638 DOI: 10.1177/0192623312468517] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 10.5] [Reference Citation Analysis]
120 Bedossa P;  FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565-575. [PMID: 24753132 DOI: 10.1002/hep.27173] [Cited by in Crossref: 285] [Cited by in F6Publishing: 264] [Article Influence: 35.6] [Reference Citation Analysis]
121 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 185] [Article Influence: 31.7] [Reference Citation Analysis]
122 Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020;119:1476-1482. [PMID: 32499209 DOI: 10.1016/j.jfma.2020.05.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Brunt EM. Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation. Int J Mol Sci. 2016;17:pii: E97. [PMID: 26771611 DOI: 10.3390/ijms17010097] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
124 Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104-1111. [PMID: 27091184 DOI: 10.1007/s00125-016-3944-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
125 Debes JD, de Knegt RJ, Boonstra A. The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New Antivirals. Transplantation. 2017;101:910-915. [PMID: 28045877 DOI: 10.1097/tp.0000000000001623] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
126 Brunt EM, Kleiner DE. When is it NAFLD and when is it ALD? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease. Chichester: John Wiley & Sons, Ltd; 2016. pp. 72-81. [DOI: 10.1002/9781118924938.ch9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Ren H, Yang D, Xu H, Pang K, Shi Y, Guan Q, Yang Z. Effect of breath holding at the end of the inspiration and expiration phases on liver stiffness measured by 2D-MR elastography. Abdom Radiol (NY) 2021;46:2516-26. [PMID: 33386913 DOI: 10.1007/s00261-020-02893-w] [Reference Citation Analysis]
128 Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, Pavlides M, Sanyal AJ, Noureddin M, Banerjee R, Dennis A, Harrison S. Clinical Utility of MRI Biomarkers for Identifying NASH Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01056-9. [PMID: 34626833 DOI: 10.1016/j.cgh.2021.09.041] [Reference Citation Analysis]
129 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 206] [Cited by in F6Publishing: 186] [Article Influence: 34.3] [Reference Citation Analysis]
130 Li J, Yu J, Peng XY, Du TT, Wang JJ, Tong J, Lu GL, Wu XW. Acoustic Radiation Force Impulse (ARFI) Elastography and Serological Markers in Assessment of Liver Fibrosis and Free Portal Pressure in Patients with Hepatitis B. Med Sci Monit. 2017;23:3585-3592. [PMID: 28735336 DOI: 10.12659/msm.905896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
131 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD. Hepatol Commun 2020;4:66-76. [PMID: 31909356 DOI: 10.1002/hep4.1445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
132 Bernal-reyes R, Castro-narro G, Malé-velázquez R, Carmona-sánchez R, González-huezo M, García-juárez I, Chávez-tapia N, Aguilar-salinas C, Aiza-haddad I, Ballesteros-amozurrutia M, Bosques-padilla F, Castillo-barradas M, Chávez-barrera J, Cisneros-garza L, Flores-calderón J, García-compeán D, Gutiérrez-grobe Y, Higuera de la Tijera M, Kershenobich-stalnikowitz D, Ladrón de Guevara-cetina L, Lizardi-cervera J, López-cossio J, Martínez-vázquez S, Márquez-guillén E, Méndez-sánchez N, Moreno-alcantar R, Poo-ramírez J, Ramos-martínez P, Rodríguez-hernández H, Sánchez-ávila J, Stoopen-rometti M, Torre-delgadillo A, Torres-villalobos G, Trejo-estrada R, Uribe-esquivel M, Velarde-ruiz Velasco J. The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019;84:69-99. [DOI: 10.1016/j.rgmxen.2019.02.003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol 2014; 20(26): 8364-8376 [PMID: 25024595 DOI: 10.3748/wjg.v20.i26.8364] [Cited by in CrossRef: 99] [Cited by in F6Publishing: 93] [Article Influence: 12.4] [Reference Citation Analysis]
134 Pan Q, Fan JG. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. Hepatobiliary Pancreat Dis Int 2019;18:1-3. [PMID: 30611667 DOI: 10.1016/j.hbpd.2018.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/S10620-016-4052-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Petts G, Lloyd K, Goldin R. Fatty liver disease. Diagnostic Histopathology 2014;20:102-8. [DOI: 10.1016/j.mpdhp.2014.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
137 Cimini FA, Arena A, Barchetta I, Tramutola A, Ceccarelli V, Lanzillotta C, Fontana M, Bertoccini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano C, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E. Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. Biochim Biophys Acta Mol Basis Dis 2019;1865:1490-501. [PMID: 30826467 DOI: 10.1016/j.bbadis.2019.02.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
138 Yang J, He L, Gao M, Xiao F, Zhang F, Wang S, Shu Y, Ye X, Qu W, Li L, Wei H. Collagen β(1-O) galactosyltransferase 2 deficiency contributes to lipodystrophy and aggravates NAFLD related to HMW adiponectin in mice. Metabolism 2021;120:154777. [PMID: 33865898 DOI: 10.1016/j.metabol.2021.154777] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Anastasopoulos NT, Lianos GD, Tatsi V, Karampa A, Goussia A, Glantzounis GK. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1025-33. [PMID: 32746645 DOI: 10.1080/17474124.2020.1802244] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
140 Leite C, Starosta RT, Trindade EN, de Melo Monteiro E, Pereira PF, Trindade MRM, Álvares-da-Silva MR, Cerski CTS. Elastic Fibers Density: a New Parameter of Improvement of NAFLD in Bariatric Surgery Patients. Obes Surg 2020;30:3839-46. [PMID: 32451920 DOI: 10.1007/s11695-020-04722-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology 2017;65:2100-9. [DOI: 10.1002/hep.29068] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 12.8] [Reference Citation Analysis]
142 Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM, Kleemann R, van den Hoek AM. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One 2014;9:e115922. [PMID: 25535951 DOI: 10.1371/journal.pone.0115922] [Cited by in Crossref: 183] [Cited by in F6Publishing: 176] [Article Influence: 22.9] [Reference Citation Analysis]
143 Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Jouness RI, Saponaro C. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107-116. [PMID: 26473614 DOI: 10.1002/hep.28287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
144 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease. Intern Med 2020;59:329-38. [PMID: 31534089 DOI: 10.2169/internalmedicine.3555-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Sazci A, Ozel MD, Ergul E, Aygun C. Association of nicotinamide-N-methyltransferase gene rs694539 variant with patients with nonalcoholic steatohepatitis. Genet Test Mol Biomarkers 2013;17:849-53. [PMID: 23964925 DOI: 10.1089/gtmb.2013.0309] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
146 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
147 Tomaselli S, Panera N, Gallo A, Alisi A. Circulating miRNA profiling to identify biomarkers of dysmetabolism. Biomark Med. 2012;6:729-742. [PMID: 23227838 DOI: 10.2217/bmm.12.91] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
148 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
149 Sarkar S, Matsukuma KE, Spencer B, Chen S, Olson KA, Badawi RD, Corwin MT, Wang G. Dynamic Positron Emission Tomography/Computed Tomography Imaging Correlate of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31442-7. [PMID: 33075553 DOI: 10.1016/j.cgh.2020.10.029] [Reference Citation Analysis]
150 Brunt EM. Surgical assessment of significant steatosis in donor livers: the beginning of the end for frozen-section analysis? Liver Transpl 2013;19:360-1. [PMID: 23447099 DOI: 10.1002/lt.23609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
151 Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, Pender J, Pomp A, Roerig J, Machado LL, Wolfe BM, Belle SH; LABS Consortium. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34:98-107. [PMID: 24782263 DOI: 10.1055/s-0034-1371083] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
152 Spolding B, Connor T, Wittmer C, Abreu LL, Kaspi A, Ziemann M, Kaur G, Cooper A, Morrison S, Lee S, Sinclair A, Gibert Y, Trevaskis JL, Roth JD, El-Osta A, Standish R, Walder K. Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat). PLoS One 2014;9:e92656. [PMID: 24651520 DOI: 10.1371/journal.pone.0092656] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
153 Zheng RD, Chen JN, Zhuang QY, Lu YH, Chen J, Chen BF. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci. 2013;10:641-646. [PMID: 23569427 DOI: 10.7150/ijms.5649] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
154 Vos MB, Dimick-santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE, Adda N, Baldyga W, Banerjee R, Behling C, Boulos S, Burgess G, Calboli D, Charles E, Christian R, Cohen-bacrie C, Cosma-roman D, Danzer C, Delaet I, Delegge M, Dimick-santos L, Diprospero N, Donohue K, Fischer L, Fitzpatrick E, Fried M, Hagerty D, Hale P, Hildick K, Hum D, Jamil K, Jiang L, Karpen S, Kelly M, Kleiner DE, Kohli R, Kordy K, Krieger N, Lavine J, Lee L, Lefebvre E, Lopez P, Lyons E, Malahias L, Megnien S, Mehta R, Mesenbrink P, Miller V, Minnick P, Murray C, Nghiem T, Nicholson N, Noviello S, Omokaro SO, Pang W, Percival L, Peres D, Powell M, Roman D, Root M, Sampson C, Sanyal A, Schabel E, Schwarz K, Schwimmer JB, Seyedkazemi S, Shapiro D, Shringarpure R, Silberg D, Smith E, Socha P, Squires R, Szitanyi P, Taminiau J, Torstenson R, Treem W, Vig P, Vos M, Yamashita M, Zemel M. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157:1448-1456.e1. [DOI: 10.1053/j.gastro.2019.08.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
155 Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemasa K, Yasui K, Minami M, Imai S, Itoh Y. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients: ALT in NASH progression. Hepatol Res 2015;45:E53-61. [DOI: 10.1111/hepr.12456] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
156 Kuroda H, Fujiwara Y, Abe T, Nagasawa T, Oguri T, Noguchi S, Kamiyama N, Takikawa Y. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. PLoS One 2021;16:e0249493. [PMID: 33826669 DOI: 10.1371/journal.pone.0249493] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
158 Xu R, Tao A, Zhang S, Zhang M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys Sin (Shanghai). 2013;45:726-733. [PMID: 23786840 DOI: 10.1093/abbs/gmt065] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
159 Melino M, Gadd VL, Alexander KA, Beattie L, Lineburg KE, Martinez M, Teal B, Le Texier L, Irvine KM, Miller GC. Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. Am J Pathol. 2016;186:524-538. [PMID: 26762581 DOI: 10.1016/j.ajpath.2015.10.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
160 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. BMC Gastroenterol 2021;21:434. [PMID: 34798835 DOI: 10.1186/s12876-021-02020-z] [Reference Citation Analysis]
161 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 15.9] [Reference Citation Analysis]
162 Schulien I, Hockenjos B, Schmitt-Graeff A, Perdekamp MG, Follo M, Thimme R, Hasselblatt P. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. Cell Death Differ 2019;26:1688-99. [PMID: 30778201 DOI: 10.1038/s41418-018-0239-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
163 Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930-1940. [PMID: 23696515 DOI: 10.1002/hep.26455] [Cited by in Crossref: 286] [Cited by in F6Publishing: 257] [Article Influence: 31.8] [Reference Citation Analysis]
164 Tada T, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. J Med Ultrasonics 2020;47:511-20. [DOI: 10.1007/s10396-020-01058-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
165 Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology 2019;70:522-31. [PMID: 30549292 DOI: 10.1002/hep.30418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
166 Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34. [PMID: 28107283 DOI: 10.1097/MPG.0000000000001482] [Cited by in Crossref: 306] [Cited by in F6Publishing: 133] [Article Influence: 76.5] [Reference Citation Analysis]
167 Sid V, Shang Y, Siow YL, Hewage SM, House JD, O K. Folic Acid Supplementation Attenuates Chronic Hepatic Inflammation in High-Fat Diet Fed Mice. Lipids. 2018;53:709-716. [PMID: 30252139 DOI: 10.1002/lipd.12084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
168 Unamuno X, Gómez-Ambrosi J, Ramírez B, Rodríguez A, Becerril S, Valentí V, Moncada R, Silva C, Salvador J, Frühbeck G, Catalán V. Dermatopontin, A Novel Adipokine Promoting Adipose Tissue Extracellular Matrix Remodelling and Inflammation in Obesity. J Clin Med 2020;9:E1069. [PMID: 32283761 DOI: 10.3390/jcm9041069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
169 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
170 Sarkar S, Corwin MT, Olson KA, Stewart SL, Liu CH, Badawi RD, Wang G. Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic 18F-FDG PET. AJR Am J Roentgenol. 2019;212:529-537. [PMID: 30673340 DOI: 10.2214/ajr.18.20012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
171 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/s10620-016-4062-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
172 Tai CM, Huang CK, Tu HP, Hwang JC, Yeh ML, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients. Medicine (Baltimore). 2016;95:e3120. [PMID: 27015186 DOI: 10.1097/md.0000000000003120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
173 Bedossa P, Kleiner DE. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 223-47. [DOI: 10.1007/978-3-319-20538-0_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Schwen LO, Schenk A, Kreutz C, Timmer J, Bartolomé Rodríguez MM, Kuepfer L, Preusser T. Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics Simulations. PLoS One 2015;10:e0133653. [PMID: 26222615 DOI: 10.1371/journal.pone.0133653] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
175 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
176 Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. J Formos Med Assoc 2021;120:68-77. [PMID: 32654868 DOI: 10.1016/j.jfma.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
177 Payne F, Lim K, Girousse A, Brown RJ, Kory N, Robbins A, Xue Y, Sleigh A, Cochran E, Adams C, Dev Borman A, Russel-Jones D, Gorden P, Semple RK, Saudek V, O'Rahilly S, Walther TC, Barroso I, Savage DB. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc Natl Acad Sci U S A 2014;111:8901-6. [PMID: 24889630 DOI: 10.1073/pnas.1408523111] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 10.3] [Reference Citation Analysis]
178 Torquato P, Giusepponi D, Alisi A, Galarini R, Bartolini D, Piroddi M, Goracci L, Di Veroli A, Cruciani G, Crudele A, Nobili V, Galli F. Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH. Sci Rep 2019;9:2045. [PMID: 30765737 DOI: 10.1038/s41598-018-37209-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
179 St-Jules DE, Watters CA, Brunt EM, Wilkens LR, Novotny R, Belt P, Lavine JE. Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2013;57:627-633. [PMID: 24177784 DOI: 10.1097/mpg.0b013e3182a1df77] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
180 Satapathy SK, Banerjee P, Pierre JF, Higgins D, Dutta S, Heda R, Khan SD, Mupparaju VK, Mas V, Nair S, Eason JD, Kleiner DE, Maluf DG. Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplant Direct 2020;6:e625. [PMID: 33204823 DOI: 10.1097/TXD.0000000000001033] [Reference Citation Analysis]
181 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol 2018;18:165. [PMID: 30400829 DOI: 10.1186/s12876-018-0900-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
182 de la Monte SM, Tong M, Agarwal AR, Cadenas E. Tobacco Smoke-Induced Hepatic Injury with Steatosis, Inflammation, and Impairments in Insulin and Insulin-Like Growth Factor Signaling. J Clin Exp Pathol 2016;6:269. [PMID: 27525191 DOI: 10.4172/2161-0681.1000269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
183 Chen YC, Hsu CW, Jeng WJ, Lin CY. Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients. Dig Dis Sci 2021. [PMID: 33569664 DOI: 10.1007/s10620-020-06761-x] [Reference Citation Analysis]
184 Nikeghbalian S, Rahimi R, Nikoupour H, Soleimani N, Vakili S, Zal F, Kaveh Baghbahadorani F. Correlation between HDL2, HDL3 and serum ferritin levels with fatty liver and NAFLD activity score (NAS) in liver histology of organ donors. BMC Gastroenterol 2021;21:405. [PMID: 34706656 DOI: 10.1186/s12876-021-01958-4] [Reference Citation Analysis]
185 Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One. 2013;8:e58895. [PMID: 23516571 DOI: 10.1371/journal.pone.0058895] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
186 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1378] [Article Influence: 246.3] [Reference Citation Analysis]
187 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H, Sorin Y, Fujiyama S, Sezaki H, Hosaka T. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int. 2016;10:647-656. [PMID: 27074850 DOI: 10.1007/s12072-016-9729-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
188 Wu L, Zhou J, Cai Q, Huang Y, Xie D, Gao Z, Deng H. Liver Fibrosis is Associated with NAFLD Activity Score in Chronic Hepatitis B Patients with Liver Steatosis. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.84182] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
189 Homeyer A, Hammad S, Schwen LO, Dahmen U, Höfener H, Gao Y, Dooley S, Schenk A. Focused scores enable reliable discrimination of small differences in steatosis. Diagn Pathol 2018;13:76. [PMID: 30231920 DOI: 10.1186/s13000-018-0753-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
190 Islek EE, Sazci A, Ozel MD, Aygun C. Genetic variants in the PNPLA3 gene are associated with nonalcoholic steatohepatitis. Genet Test Mol Biomarkers 2014;18:489-96. [PMID: 24831885 DOI: 10.1089/gtmb.2014.0019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
191 Solís N, Pizarro M, Quintero P, Arab JP, Riquelme A, Padilla O, Carrasco G, Pirola CJ, Sookoian S, Arrese M. Effects of bile acid sequestration on hepatic steatosis in obese mice. Annals of Hepatology 2014;13:105-12. [DOI: 10.1016/s1665-2681(19)30911-1] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
192 Hsiang JC, Wong GL, Chan HL, Chan AW, Chim AM, Wong VW. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther. 2014;40:716-726. [PMID: 25039861 DOI: 10.1111/apt.12874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
193 Choi W, Namkung J, Hwang I, Kim H, Lim A, Park HJ, Lee HW, Han KH, Park S, Jeong JS, Bang G, Kim YH, Yadav VK, Karsenty G, Ju YS, Choi C, Suh JM, Park JY. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun. 2018;9:4824. [PMID: 30446669 DOI: 10.1038/s41467-018-07287-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
194 Giraudi PJ, Gambaro SE, Ornelas Arroyo S, Chackelevicius CM, Giuricin M, Silvestri M, Macor D, Crocé LS, Bonazza D, Soardo G, de Manzini N, Zanconati F, Tiribelli C, Palmisano S, Rosso N. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. Liver Int 2018;38:155-63. [PMID: 28650518 DOI: 10.1111/liv.13505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
195 Gart E, Salic K, Morrison MC, Caspers M, van Duyvenvoorde W, Heijnk M, Giera M, Bobeldijk-Pastorova I, Keijer J, Storsve AB, Hals PA, Kleemann R. Krill Oil Treatment Increases Distinct PUFAs and Oxylipins in Adipose Tissue and Liver and Attenuates Obesity-Associated Inflammation via Direct and Indirect Mechanisms. Nutrients 2021;13:2836. [PMID: 34444996 DOI: 10.3390/nu13082836] [Reference Citation Analysis]
196 Almanza D, Gharaee-Kermani M, Zhilin-Roth A, Rodriguez-Nieves JA, Colaneri C, Riley T, Macoska JA. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Dig Dis Sci 2019;64:1257-69. [PMID: 30519850 DOI: 10.1007/s10620-018-5398-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
197 Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ;  Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2:e1912565. [PMID: 31584681 DOI: 10.1001/jamanetworkopen.2019.12565] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 26.7] [Reference Citation Analysis]
198 Yousef MH, Al Juboori A, Albarrak AA, Ibdah JA, Tahan V. Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients. World J Gastrointest Pathophysiol 2017; 8(3): 100-107 [PMID: 28868179 DOI: 10.4291/wjgp.v8.i3.100] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
199 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
200 Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, Ciancio A, Abate ML, Cammà C, Smedile A, Craxì A, Saracco GM, Bugianesi E. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver Int 2018;38:715-23. [DOI: 10.1111/liv.13612] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
201 Gart E, Souto Lima E, Schuren F, de Ruiter CGF, Attema J, Verschuren L, Keijer J, Salic K, Morrison MC, Kleemann R. Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD. Int J Mol Sci 2018;20:E1. [PMID: 30577415 DOI: 10.3390/ijms20010001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
202 Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. APMIS. 2017;125:962-973. [PMID: 29076589 DOI: 10.1111/apm.12742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
203 Karlas T, Dietrich A, Peter V, Wittekind C, Lichtinghagen R, Garnov N, Linder N, Schaudinn A, Busse H, Prettin C, Keim V, Tröltzsch M, Schütz T, Wiegand J. Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. PLoS One 2015;10:e0141649. [PMID: 26528818 DOI: 10.1371/journal.pone.0141649] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
204 Reis-Júnior P, Tanigawa R, de Mesquita GHA, Basan N, Alves V, D'Albuquerque LAC, Andraus W. Steatosis and steatohepatitis found in adults after death due to non-burn trauma. Clinics (Sao Paulo) 2019;74:e1070. [PMID: 31618320 DOI: 10.6061/clinics/2019/e1070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Budelmann D, Laue H, Weiss N, Dahmen U, D'Alessandro LA, Biermayer I, Klingmüller U, Ghallab A, Hassan R, Begher-Tibbe B, Hengstler JG, Schwen LO. Automated Detection of Portal Fields and Central Veins in Whole-Slide Images of Liver Tissue. J Pathol Inform 2022;13:100001. [PMID: 35242441 DOI: 10.1016/j.jpi.2022.100001] [Reference Citation Analysis]
206 Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver Int 2020;40:2242-51. [PMID: 32652744 DOI: 10.1111/liv.14593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
207 Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015;13:27-36. [PMID: 24909907 DOI: 10.1016/j.cgh.2014.04.039] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 10.8] [Reference Citation Analysis]
208 Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res. 2014;164:312-322. [PMID: 25028077 DOI: 10.1016/j.trsl.2014.06.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
209 Samji NS, Heda R, Kovalic AJ, Satapathy SK. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. Gastroenterology Clinics of North America 2020;49:151-64. [DOI: 10.1016/j.gtc.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Donath H, Woelke S, Theis M, Heß U, Knop V, Herrmann E, Krauskopf D, Kieslich M, Schubert R, Zielen S. Progressive Liver Disease in Patients With Ataxia Telangiectasia. Front Pediatr 2019;7:458. [PMID: 31788461 DOI: 10.3389/fped.2019.00458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
211 Chi ZC. Relationship between non-alcoholic fatty liver disease and cardiovascular disease. Shijie Huaren Xiaohua Zazhi 2020; 28(9): 313-329 [DOI: 10.11569/wcjd.v28.i9.313] [Reference Citation Analysis]
212 Guo B, Li Z. Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. Front Genet 2014;5:242. [PMID: 25120559 DOI: 10.3389/fgene.2014.00242] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
213 Goh YQ, Cheam G, Wang Y. Understanding Choline Bioavailability and Utilization: First Step Toward Personalizing Choline Nutrition. J Agric Food Chem 2021. [PMID: 34392687 DOI: 10.1021/acs.jafc.1c03077] [Reference Citation Analysis]
214 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
215 Guillaume M, Ratziu V. Pharmacological agents for nonalcoholic steatohepatitis. Hepatol Int 2013;7 Suppl 2:833-41. [PMID: 26202298 DOI: 10.1007/s12072-013-9482-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
216 Radhakrishnan S, Ke JY, Pellizzon MA. Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models. Curr Dev Nutr 2020;4:nzaa078. [PMID: 32494762 DOI: 10.1093/cdn/nzaa078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
217 Akuta N, Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Ikeda K, Kumada H. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. Gut Liver. 2016;10:437-445. [PMID: 26610348 DOI: 10.5009/gnl15163] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
218 Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis 2015;11:888-94. [PMID: 25240529 DOI: 10.1016/j.soard.2014.07.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
219 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 395.6] [Reference Citation Analysis]
220 Shearn CT, Orlicky DJ, McCullough RL, Jiang H, Maclean KN, Mercer KE, Stiles BL, Saba LM, Ronis MJ, Petersen DR. Liver-Specific Deletion of Phosphatase and Tensin Homolog Deleted on Chromosome 10 Significantly Ameliorates Chronic EtOH-Induced Increases in Hepatocellular Damage. PLoS One 2016;11:e0154152. [PMID: 27124661 DOI: 10.1371/journal.pone.0154152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
221 Kwanten WJ, Martinet W, Michielsen PP, Francque SM. Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: A controversial issue. World J Gastroenterol 2014; 20(23): 7325-7338 [PMID: 24966603 DOI: 10.3748/wjg.v20.i23.7325] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 58] [Article Influence: 7.6] [Reference Citation Analysis]
222 Kleiner DE, Bedossa P. Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. Gastroenterology 2015;149:1305-8. [DOI: 10.1053/j.gastro.2015.09.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
223 Liangpunsakul S, Kleiner DE. The alcoholic hepatitis histologic score: structured prognostic biopsy evaluation comes to alcoholic hepatitis. Gastroenterology 2014;146:1156-8. [PMID: 24680970 DOI: 10.1053/j.gastro.2014.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
224 Jia Q, Li C, Xia Y, Zhang Q, Wu H, Du H, Liu L, Wang C, Shi H, Guo X, Liu X, Sun S, Wang X, Zhou M, Zhao H, Song K, Wu Y, Niu K. Association between complement C3 and prevalence of fatty liver disease in an adult population: a cross-sectional study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) cohort study. PLoS One 2015;10:e0122026. [PMID: 25856141 DOI: 10.1371/journal.pone.0122026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]